For Sponsors & CROs
A single point of contact to Australia’s oncology trial sites, from first-time-in-human feasibility through to trial approval and close-out.
A coordinated route into Australia’s oncology trial sites
CTA works with some of the world’s largest pharmaceutical companies and CROs, as well as emerging biotechnology companies, to support drug development in Australia. We operate across national and international Phase 0–III trials, including first-time-in-human studies, with molecules ranging from small chemical agents to antibodies and therapeutic vaccines.
Feasibility Evaluation
CTA is the unified contact point for sponsors and CROs for First Time in Human feasibility across the network. We support the whole process to improve communication, and advise on the sites best matched to your study by capability and therapeutic focus.
Early Phase Trials
Australia is a recognised hub for early phase trials. CTA’s Phase I Group comprises the sites conducting the majority of Phase I cancer trials in the country, and our key opinion leaders can review pre-clinical data and quickly offer impartial recommendations.
Trial Design and Protocol Advice
Advice on trial design and protocol development, and coordinated discussions with experienced investigators.
Partnering With CTA
A single point of contact to our network of members, established and robust communication channels, dedicated staff for ethics, governance, budgets and contracts, and a world-class Clinical Trial Management System.
Partnership, efficiency & quality
Partnership
CTA understands what pharmaceutical and biotech companies need to run a successful trial, and gives you a single point of contact to our network through established, robust communication channels.
Efficiency
We coordinate start-up from feasibility evaluation and ethics submissions through budget and contract negotiation to trial approval, with rigorous internal monitoring of timelines and time to approval.
Quality
Ethics and governance specialists make sure HREC submission requirements are met and queries are kept to a minimum.
From feasibility to close-out
One team coordinates the work around your study, from the first feasibility enquiry through to final close-out.
Feasibility
One enquiry to CTA starts a coordinated First Time in Human feasibility review across the network. We advise on the sites best matched to your study by capability and therapeutic focus.
Ethics & Governance
Specialist staff prepare the HREC and governance submissions so requirements are met first time, targeting the best committee deadlines to minimise time to approval.
Budgets & Contracts
CTA compiles and negotiates clinical trial budgets and contracts with each site, keeping negotiations moving while supporting the financial sustainability of member trial units.
Post-Approval
After approval, CTA handles amendments and ongoing ethics and governance responses, maintaining rapid turnaround as your trial progresses.
Billing & Close-Out
Per-patient fees, additional assessments and annual fees are tracked and invoiced throughout, with rapid close-out accounting when the trial finishes.
Planning a study in Australia?
Talk to the team about feasibility, early phase trials or partnering with CTA.
